BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 28720054)

  • 1. Impact of novel agents on patient-relevant outcomes in patients with previously untreated chronic lymphocytic leukemia who are not eligible for fludarabine-based therapy.
    Singh M; Mealing S; Baculea S; Cote S; Whelan J
    J Med Econ; 2017 Oct; 20(10):1066-1073. PubMed ID: 28720054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United States.
    Chatterjee A; Shapouri S; Manzoor BS; Ravelo A; Sail K; Qendri V; van de Wetering G; Davids MS
    J Manag Care Spec Pharm; 2021 Nov; 27(11):1532-1544. PubMed ID: 34714110
    [No Abstract]   [Full Text] [Related]  

  • 3. A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia.
    Cheung MC; Mittmann N; Owen C; Abdel-Samad N; Fraser GAM; Lam S; Crump M; Sperlich C; van der Jagt R; Prica A; Couban S; Woyach JA; Ruppert AS; Booth AM; Mandrekar SJ; McDonald G; Shepherd LE; Yen H; Chen BE; Hay AE
    Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):766-774. PubMed ID: 34334330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A network meta-analysis of progression free survival and overall survival in first-line treatment of chronic lymphocytic leukemia.
    Ladyzynski P; Molik M; Foltynski P
    Cancer Treat Rev; 2015 Feb; 41(2):77-93. PubMed ID: 25512118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A canadian perspective on the first-line treatment of chronic lymphocytic leukemia.
    Owen C; Bence-Bruckler I; Chamakhi I; Toze C; Assaily W; Christofides A; Robinson S
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):303-13. PubMed ID: 25937158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Efficacy of Ibrutinib Versus Obinutuzumab + Chlorambucil in First-Line Treatment of Chronic Lymphocytic Leukemia: A Matching-Adjusted Indirect Comparison.
    Van Sanden S; Baculea S; Diels J; Cote S
    Adv Ther; 2017 Jul; 34(7):1650-1661. PubMed ID: 28573505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies.
    Robak T; Burger JA; Tedeschi A; Barr PM; Owen C; Bairey O; Hillmen P; Simpson D; Grosicki S; Devereux S; McCarthy H; Coutre SE; Quach H; Gaidano G; Maslyak Z; Stevens DA; Moreno C; Gill DS; Flinn IW; Gribben JG; Mokatrin A; Cheng M; Styles L; James DF; Kipps TJ; Ghia P
    Am J Hematol; 2018 Nov; 93(11):1402-1410. PubMed ID: 30129285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of First-line Chronic Lymphocytic Leukemia Treatments When Full-dose Fludarabine Is Unsuitable.
    Soini E; Hautala A; Poikonen E; Becker U; Kyttälä M; Martikainen J
    Clin Ther; 2016 Apr; 38(4):889-904.e14. PubMed ID: 26970696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Routine Use of Bendamustine in Patients with Chronic Lymphocytic Leukemia: An Observational Study.
    Ninkovic M; Fiegl M; Mian M; Mondello P; Kocher F; Waldthaler C; Verdorfer I; Steurer M; Gastl G; Pircher A
    Anticancer Res; 2015 Sep; 35(9):5129-39. PubMed ID: 26254418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study.
    Cuneo A; Mato AR; Rigolin GM; Piciocchi A; Gentile M; Laurenti L; Allan JN; Pagel JM; Brander DM; Hill BT; Winter A; Lamanna N; Tam CS; Jacobs R; Lansigan F; Barr PM; Shadman M; Skarbnik AP; Pu JJ; Sehgal AR; Schuster SJ; Shah NN; Ujjani CS; Roeker L; Orlandi EM; Billio A; Trentin L; Spacek M; Marchetti M; Tedeschi A; Ilariucci F; Gaidano G; Doubek M; Farina L; Molica S; Di Raimondo F; Coscia M; Mauro FR; de la Serna J; Medina Perez A; Ferrarini I; Cimino G; Cavallari M; Cucci R; Vignetti M; Foà R; Ghia P;
    Cancer Med; 2020 Nov; 9(22):8468-8479. PubMed ID: 32969597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness of Ibrutinib Compared With Obinutuzumab With Chlorambucil in Untreated Chronic Lymphocytic Leukemia Patients With Comorbidities in the United Kingdom.
    Sinha R; Redekop WK
    Clin Lymphoma Myeloma Leuk; 2018 Feb; 18(2):e131-e142. PubMed ID: 29398648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study.
    Cuneo A; Follows G; Rigolin GM; Piciocchi A; Tedeschi A; Trentin L; Perez AM; Coscia M; Laurenti L; Musuraca G; Farina L; Delgado AR; Orlandi EM; Galieni P; Mauro FR; Visco C; Amendola A; Billio A; Marasca R; Chiarenza A; Meneghini V; Ilariucci F; Marchetti M; Molica S; Re F; Gaidano G; Gonzalez M; Forconi F; Ciolli S; Cortelezzi A; Montillo M; Smolej L; Schuh A; Eyre TA; Kennedy B; Bowles KM; Vignetti M; de la Serna J; Moreno C; Foà R; Ghia P;
    Haematologica; 2018 Jul; 103(7):1209-1217. PubMed ID: 29674504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.
    Woyach JA; Ruppert AS; Heerema NA; Zhao W; Booth AM; Ding W; Bartlett NL; Brander DM; Barr PM; Rogers KA; Parikh SA; Coutre S; Hurria A; Brown JR; Lozanski G; Blachly JS; Ozer HG; Major-Elechi B; Fruth B; Nattam S; Larson RA; Erba H; Litzow M; Owen C; Kuzma C; Abramson JS; Little RF; Smith SE; Stone RM; Mandrekar SJ; Byrd JC
    N Engl J Med; 2018 Dec; 379(26):2517-2528. PubMed ID: 30501481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-Effectiveness Model for Chemoimmunotherapy Options in Patients with Previously Untreated Chronic Lymphocytic Leukemia Unsuitable for Full-Dose Fludarabine-Based Therapy.
    Becker U; Briggs AH; Moreno SG; Ray JA; Ngo P; Samanta K
    Value Health; 2016 Jun; 19(4):374-82. PubMed ID: 27325329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Efficacy of Acalabrutinib in Frontline Treatment of Chronic Lymphocytic Leukemia: A Systematic Review and Network Meta-analysis.
    Davids MS; Waweru C; Le Nouveau P; Padhiar A; Singh G; Abhyankar S; Leblond V
    Clin Ther; 2020 Oct; 42(10):1955-1974.e15. PubMed ID: 33032842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Bendamustine and Ibrutinib in Previously Untreated Patients With Chronic Lymphocytic Leukemia: Indirect Comparison.
    Andrasiak I; Rybka J; Knopinska-Posluszny W; Wrobel T
    Clin Lymphoma Myeloma Leuk; 2017 May; 17(5):268-273. PubMed ID: 28395851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment.
    Hallek M
    Am J Hematol; 2017 Sep; 92(9):946-965. PubMed ID: 28782884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Systematic Review and Network Meta-Analysis to Evaluate the Comparative Efficacy of Interventions for Unfit Patients with Chronic Lymphocytic Leukemia.
    Städler N; Shang A; Bosch F; Briggs A; Goede V; Berthier A; Renaudin C; Leblond V
    Adv Ther; 2016 Oct; 33(10):1814-1830. PubMed ID: 27535291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-utility analysis of venetoclax in combination with obinutuzumab as first-line treatment of chronic lymphocytic leukaemia in Spain.
    Moreno-Martínez E; De la Serna-Torroba J; Escudero-Vilaplana V; Hernández-Rivas JÁ; Sánchez-Cuervo M; Sánchez-Hernández R
    Farm Hosp; 2022 Apr; 46(3):121-132. PubMed ID: 36183205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician.
    Byrd JC; Jones JJ; Woyach JA; Johnson AJ; Flynn JM
    J Clin Oncol; 2014 Sep; 32(27):3039-47. PubMed ID: 25049322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.